Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.12.2 (
MEK
)
18,161
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Approximately one-half of advanced cutaneous melanomas have a V600 mutation in the BRAF gene that activates the mitogen-activated protein kinase pathway. The combination of BRAF plus
MEK
inhibitors is one of the most effective treatments for these patients. Severe neurological toxicities have been reported in the literature. However, these toxicities are very rare. Here, we present one patient with acute motor and sensory axonal neuropathy, which is a subtype of
Guillain-Barre syndrome
, secondary to treatment with
MEK
inhibitors. This side effect had never been described as related to these agents. However, the mitogen-activated protein kinase pathway can be involved in
Guillain-Barre syndrome
, and awareness of early neurological injury signs is important in patients treated with
MEK
inhibitors.
...
PMID:Acute motor and sensory axonal neuropathy related to treatment with MEK inhibitors in a patient with advanced melanoma. 2887 88
